Streetbeat News

Stock Prices

CRK

Comstock Resources announced that its majority shareholder, Jerry Jones, will invest an additional $100.45M through two entities he controls. This investment will be for 12.50 million shares at $8.036 each, based on the average closing prices up to March 20, 2024. Post-investment, Jones's ownership will increase to approximately 67% from 65%.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 9:49 pm

RDDT

Reddit has announced the pricing of its IPO at $34 per share, at the high end of its expected range. The company is offering 22 million shares, with trading on the NYSE under the ticker 'RDDT' starting on March 21, 2024.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 9:47 pm

ELA

Envela (AMEX:ELA) reported Q4 earnings with an EPS of $0.05, missing estimates by -17.0% and showing a revenue decline of $10.73 million from the previous year. This follows a pattern of missed EPS estimates and subsequent share price drops.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 9:35 pm

FIVE

GES

HOFV

In Wednesday's after-market session, several consumer discretionary stocks showed notable movements. Guess (GES) and Hall Of Fame Resort (HOFV) reported their Q4 earnings, leading to a 10.5% increase in GES shares and an 8.55% rise in HOFV shares. Other gainers included Kaival Brands Innovations (KAVL), Nova Lifestyle (NVFY), Qurate Retail (QRTEB), and Kaixin Auto Holdings (KXIN). On the downside, Five Below (FIVE) saw a 12.8% drop after its Q4 earnings report, with other losers being SRIVARU Holding (SVMH), Aarons (AAN), Visionary Holdings (GV), SRM Entertainment (SRM), and Red Robin Gourmet Burgers (RRGB).

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 9:34 pm

BPTS

ETAO

FRES

JAGX

LPTX

XTLB

In Wednesday's after-market session, several healthcare stocks experienced significant movements. XTL Biopharmaceuticals, Leap Therapeutics, and Jaguar Health were among the top gainers, with increases of 13.9%, 11.21%, and 10.94% respectively. On the downside, Biophytis, Fresh2 Group, and Etao International Co led the losers, with declines of 20.8%, 16.63%, and 14.01% respectively. Notably, Leap Therapeutics' rise followed its Q4 earnings release, and Avinger also reported its Q4 earnings.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 9:34 pm

AERT

SCS

In Wednesday's after-market session, several industrials stocks saw significant movements. Aeries Technology, Astra Space, Swvl Hldgs, Agrify, AERWINS Technologies, and Energous experienced gains, while Steelcase, Lucas GC, Baiyu Holdings, BioNexus Gene Lab, voxeljet, and noco-noco faced declines. Notably, Steelcase's drop followed its Q4 earnings release.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 9:34 pm

LAW

NSYS

PRST

In Wednesday's after-market session, several Information Technology stocks showed notable movements. Nortech Systems (NSYS) and Micron Technology (MU) emerged as significant gainers with 19.3% and 14.3% increases in their stock prices, respectively, following their earnings releases. On the losing end, Presto Automation (PRST) and CS Disco (LAW) saw declines of 6.7% and 6.64%. Other stocks like Banzai International (BNZI), Bridgeline Digital (BLIN), Intapp (INTA), and Indie Semiconductor (INDI) also experienced gains, while Blend Labs (BLND), Datasea (DTSS), Alpha Technology Group (ATGL), and Akoustis Technologies (AKTS) faced declines.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 9:34 pm

MVLA

Movella has announced its voluntary delisting from the Nasdaq Global Market, with the expected last trading day of its Common Stock and Warrants on or about April 11, 2024.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 9:31 pm

HLVX

HilleVax (NASDAQ:HLVX) reported Q4 earnings, beating estimates with an EPS of $-0.78 against an expected $-0.83, a 6.0% beat. However, revenue remained unchanged from the previous year. Following a similar earnings beat last quarter, HLVX's share price increased by 6.0% the next day.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 9:30 pm

FUSN

Fusion Pharmaceuticals (NASDAQ:FUSN) reported Q4 earnings with a -15.0% miss on estimated earnings, posting an EPS of $-0.39 against an estimate of $-0.34. Revenue decreased by $140 thousand from the same period last year. The company's past earnings performance shows variability in beating EPS estimates but was followed by a 2.0% drop in share price after last quarter's earnings beat.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 9:30 pm